VOL NO REGD NO DA 1589

Wednesday, March 15, 2006

HEADLINE

POLITICS & POLICIES

METRO & COUNTRY

VIEWS & OPINIONS

EDITORIAL

LETTER TO EDITOR

COMPANY & FINANCE

BUSINESS & FINANCE

TRADE/ECONOMY

LEISURE & ENTERTAINMENT

MARKET & COMMODITIES

SPORTS

WORLD

 

FE Specials

FE Education

Urban Property

Monthly Roundup

Saturday Feature

Asia/South Asia

 

Feature

13th SAARC SUMMIT DHAKA-2005

WOMEN & ECONOMY

57th Republic Day of India

US TRADE SHOW

 

 

 

Archive

Site Search

 

HOME

COMPANY & FINANCE
 
Beximco Pharma draws Myanmar mkt expansion plan
3/15/2006
 

          Taking advantage of the exemptions of 'pharmaceutical product patent' for the least developed countries (LDCs) until 2016, as given by the Doha Declaration of Trade Related aspects of Intellectual Property rights (TRIPs), Beximco Pharmaceuticals participated in a three-day 'Pharmaceutical Product Show' in Myanmar with a massive market expansion plan, reports BDNEWS.
All the TRIPs signatory countries excepting the 50 LDCs have already implemented 'pharmaceutical product patent' in their respective countries, paving the way for pharmaceutical companies in the LDCs to reap the benefit of Doha Declaration by exporting medicines in huge volumes to the LDCs including Myanmar, a 90 per cent import dependent LDC in the South East Asia.
Beximco Pharma Chief Executive Officer Nazmul Hassan said the WTO rules have opened the prospects of good business in foreign market by big local companies like Beximco Pharma having modern quality research and development units.
He made the observation while making a keynote presentation in two seminars on the sidelines of the fair
Hassan also highlighted the impact of TRIPs on the import-based pharmaceutical sector of Myanmar and how Bangladesh could be a major source for Myanmar for patented drugs.
Explaining the rules, he said as a pharmaceutical manufacturer of an LDC, Beximco Pharma can now legally reverse- engineer patented products and sell these in the domestic market as well as in all other LDCs, non-WTO member countries and countries where product patent is not in force.
Beximco Pharma will also transfer technology and research to the Myanmar drug manufacturers if any company expresses interest, he said.
The Beximco Pharma CEO also focused on the manufacturing, overseas registration and marketing capabilities of Beximco Pharma as well as Bangladesh pharmaceutical industry, with special emphasis on its product quality, packaging and presentation.
Jointly organised by Export Promotion Bureau (EPB) of Bangladesh, Bangladesh Association of Pharmaceutical Industries (BAP) and Bangladesh Embassy in Myanmar, the three-day show was held at Hotel Sedona in the Myanmar capital from March 10 to 12, 2006.

 

 
  More Headline
Leading export sectors facing fund crisis
Beximco Pharma draws Myanmar mkt expansion plan
DSE indices mixed, CSE’s gain
Skilled manpower for proposed TATA plant to be 'brought from India'
Dollar touches Tk 72 mark
Holcim to supply cement for Mukterpur Road Bridge
BDCOM appoints Sabir MD
 

Print this page | Mail this page | Save this page | Make this page my home page

About us  |  Contact us  |  Editor's panel  |  Career opportunity | Web Mail

 

 

 

 

Copy right @ financialexpress.com